Broad-spectrum antibiotic their greater potential to disrupt a larger variety of normal human flora. After continued exposure to an antibiotic, bacteria may develop changes in their structure or function that make them resistant to the antibiotic. These resistant organisms will live, while the susceptible organisms will die, leaving the population of bacteria entirely resistant to a given antibiotics. For example, after the discovery of penicillin and its subsequent use to treat bacterial infections, bacteria were found to have begun producing an enzyme, penicillinase, which rendered the penicillin molecule inactive. In response to this newly-acquired resistance, newer penicillins were produced that could not
Antibiotic Resistance Lab Network Antibiotic Resistance Lab Network The Antibiotic Resistance Lab Network (ARLN) is a group of laboratories of the United States Centers for Disease Control and Prevention established to supplement the work of local and state public health laboratories in the identification and research of antibiotic resistance. It was created as part of the CDC's "National Action Plan for Combating Antibiotic Resistant Bacteria". The network is part of the National Center for Emerging and Zoonotic Infectious Diseases. Laboratories in this network cover seven regions and are located in Maryland, Minnesota, New York, Tennessee, Texas, Washington, and Wisconsin, as part of their state